US FDA Throws Acadia A Curveball On Nuplazid For Dementia Psychosis
Complete Response Letter Requires More Data
Acadia strikes out on potential near-term sNDA approval in a broad dementia-related psychosis indication. The firm said the agency’s view has shifted from what was previously agreed upon.
